Sandip K Mishra
Institute of Life Sciences, India
Title: Our effort to make Estrogen Receptor positive breast cancer a history
Biography
Biography: Sandip K Mishra
Abstract
Estrogen receptor positive breast cancer is a group of diseases, which cannot have one stop solution. It comes up with various complications of drug resistant and reoccurrence of the disease. Our approach is to speculate the combinatorial effort of alteration in genetics, and epigenetics towards the treatment of disease. The findings of our laboratory showed estrogen-related receptor beta (ERRβ) to be prognostic marker for breast cancer. ERRβ-mediated reduced cancer cell growth and enhanced apoptosis explains the significant association of its high expression with improved patient survival. Also, in response to treatment with plant derived extract artemisinin, upregulated expression of tumor suppressor genes along with reduced expression of oncogenes significantly associated with growth stimulating signaling pathways that suggests its efficacy as an effective drug in breast cancer treatment. Abrogated nicotine-induced increased breast tumor growth upon DZNepA treatment suggested the promising role of EZH2 inhibition in environment effected disease development. In addition, NEDD8 is an emerging molecule in the field of translational protein modification and regulation. A well-known substrate of NEDD8 is TP53. Our study elucidate that over expression of NEDDylated TP53 enhances apoptosis in breast cancer, thus suggesting that NEDDylated TP53 is active and that Noxa is one of the crucial pro-apoptotic effectors of NEDDylated TP53-mediated apoptosis and also NEDDylated TP53 induces the promoter activity of well-known cell cycle regulator p21. Significant involvement of ERRβ and NEDD8 in growing tamoxifen resistance in estrogen receptor positive breast cancer directs their combined effort towards disease progression. Therefore, a synergistic effect of modification of genes in addition to treatment with promising growth inhibiting drugs can be proved to be an effective strategy towards breast cancer treatment and combating resistance towards drugs.